Explore JANX's promising early data in prostate cancer immunotherapy. Understand market challenges, buyout rumors, and ...

Relay Therapeutics gains capital via licensing, reduces costs, and advances its promising PI3K-alpha inhibitor. See why RLAY ...

Steve brings deep experience in strategic transactions to Werewolf at this critical time,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “Werewolf is ...

And as we advanced our internal gene therapy pipeline, we also continued ... This is a good sign and shows it’s at an inflection point. In Q4, Sarepta Therapeutics reported EPS at $1.90, up ...

Century Therapeutics re-prioritizes its pipeline, focusing on CNTY-308 and CNTY-101, with extended cash runway into Q4 2026. Century Therapeutics, Inc. has announced a re-prioritization of its ...

Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators designed to restore lysosomal function in Parkinson’s disease (PD) and other neurodegenerative ...

March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq ... from this analysis will mark a significant value inflection point for the GT-02287 program and importantly, inform the ...